ATE464908T1 - Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern - Google Patents

Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern

Info

Publication number
ATE464908T1
ATE464908T1 AT05702390T AT05702390T ATE464908T1 AT E464908 T1 ATE464908 T1 AT E464908T1 AT 05702390 T AT05702390 T AT 05702390T AT 05702390 T AT05702390 T AT 05702390T AT E464908 T1 ATE464908 T1 AT E464908T1
Authority
AT
Austria
Prior art keywords
antibodies
treating osteoarthritis
osteoarthritis
treating
antagonists
Prior art date
Application number
AT05702390T
Other languages
English (en)
Inventor
Susan Elizabeth Bove
Kenneth Stanley Kilgore
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34885980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE464908(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE464908T1 publication Critical patent/ATE464908T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05702390T 2004-02-11 2005-01-31 Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern ATE464908T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54381404P 2004-02-11 2004-02-11
PCT/IB2005/000240 WO2005080429A2 (en) 2004-02-11 2005-01-31 Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies

Publications (1)

Publication Number Publication Date
ATE464908T1 true ATE464908T1 (de) 2010-05-15

Family

ID=34885980

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05702390T ATE464908T1 (de) 2004-02-11 2005-01-31 Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern

Country Status (9)

Country Link
US (2) US20080145367A1 (de)
EP (1) EP1715891B2 (de)
JP (1) JP2008505054A (de)
AT (1) ATE464908T1 (de)
BR (1) BRPI0506679A (de)
CA (1) CA2555688C (de)
DE (1) DE602005020743D1 (de)
ES (1) ES2341461T5 (de)
WO (1) WO2005080429A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
DK2374818T3 (da) 2006-06-02 2013-01-21 Regeneron Pharma Højaffinitetsantistoffer mod human IL-6-receptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
JP2009545319A (ja) 2006-08-03 2009-12-24 バクシネックス，インコーポレーテッド 抗ｉｌ−６モノクローナル抗体およびその使用
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
WO2009010539A2 (de) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) form macaca fascicularis
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
SG193868A1 (en) 2007-09-26 2013-10-30 Chugai Pharmaceutical Co Ltd Modified antibody constant region
JP2009092508A (ja) * 2007-10-09 2009-04-30 Norihiro Nishimoto リウマチ治療剤の効果の予測方法
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
MX2010012031A (es) 2008-05-13 2011-01-20 Novimmune Sa Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos.
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CN102271705A (zh) 2008-12-22 2011-12-07 墨尔本大学 骨关节炎治疗
SG174428A1 (en) * 2009-03-19 2011-10-28 Chugai Pharmaceutical Co Ltd Pharmaceutical formulation containing improved antibody molecules
WO2010107109A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
TWI505838B (zh) 2010-01-20 2015-11-01 中外製藥股份有限公司 Stabilized antibody solution containing
SG10201509790YA (en) 2010-11-30 2015-12-30 Chugai Pharmaceutical Co Ltd Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly
KR20220136466A (ko) 2011-01-28 2022-10-07 사노피 바이오테크놀로지 특정 대상자 그룹의 치료 방법에 이용하기 위한 ｐｃｓｋ9에 대한 인간 항체
RU2015134562A (ru) * 2011-02-08 2018-12-24 Эббви Инк. Лечение остеоартрита и боли
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
CN113416257A (zh) 2011-11-30 2021-09-21 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
WO2014200018A1 (ja) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
WO2016044153A1 (en) * 2014-09-18 2016-03-24 Rush University Medical Center Methods for preventing or treating osteoarthritis
WO2016098356A1 (en) 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN112142844B (zh) 2015-02-05 2025-07-25 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
TWI805046B (zh) 2015-02-27 2023-06-11 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
WO2016186154A1 (ja) 2015-05-19 2016-11-24 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症（ｍｓ）患者の新規治療適用判断方法
EP3888752A1 (de) 2015-07-31 2021-10-06 MedImmune Limited Il-6-antikörper zur verwendung bei der behandlung von kardiovaskuläre krankheiten
WO2017031151A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
JP7191833B2 (ja) 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用
MX390722B (es) 2017-02-01 2025-03-21 Univ Yale Tratamiento de resistencia a diureticos.
EP3620531A4 (de) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Verfahren zur vorhersage und beurteilung der therapeutischen wirkung bei erkrankungen im zusammenhang mit il-6 und neutrophilen
KR102771895B1 (ko) 2017-10-20 2025-02-21 가꼬우호우징 효고 이카다이가쿠 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
CA3087699A1 (en) 2018-01-05 2019-07-11 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression
KR20210122810A (ko) 2019-01-31 2021-10-12 사노피 바이오테크놀로지 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체
JP7501876B2 (ja) 2019-04-17 2024-06-18 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
TW202106712A (zh) 2019-04-24 2021-02-16 美商再生元醫藥公司 類風溼性關節炎之診斷及治療方法
CA3142710A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
WO2021067749A2 (en) * 2019-10-02 2021-04-08 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for the treatment of osteoarthritis
EP4159236A4 (de) 2020-05-29 2024-08-21 Chugai Seiyaku Kabushiki Kaisha Antikörperhaltige formulierung

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT52962A (en) * 1988-03-04 1990-09-28 Sandoz Ag Process for production of medical compositions eliminating bone-absorption and promoting forming of bones
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
KR100249937B1 (ko) * 1991-04-25 2000-04-01 나가야마 오사무 인간 인터루킨-6 수용체에 대한 재구성 인간 항체
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
PT783893E (pt) * 1994-10-07 2012-05-24 Chugai Pharmaceutical Co Ltd Inibição do crescimento anormal das células sinoviais usando antagonistas de il-6 como componente ativo
US5617790A (en) * 1995-05-31 1997-04-08 P.R. Graphics Limited Apparatus for producing flexographic printing plates
US20030202977A1 (en) * 1998-11-16 2003-10-30 New York University Treatment of osteoarthritis
AR035642A1 (es) * 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
CA2467719C (en) * 2001-11-14 2015-03-17 Jill Giles-Komar Anti-il-6 antibodies, compositions, methods and uses

Also Published As

Publication number Publication date
WO2005080429A3 (en) 2006-02-23
EP1715891A2 (de) 2006-11-02
US20080145367A1 (en) 2008-06-19
WO2005080429A2 (en) 2005-09-01
US20100215654A1 (en) 2010-08-26
EP1715891B1 (de) 2010-04-21
DE602005020743D1 (de) 2010-06-02
JP2008505054A (ja) 2008-02-21
ES2341461T3 (es) 2010-06-21
ES2341461T5 (es) 2014-10-29
BRPI0506679A (pt) 2007-05-15
CA2555688C (en) 2011-11-08
EP1715891B2 (de) 2014-08-13
CA2555688A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
ATE464908T1 (de) Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
ATE425136T1 (de) Verfahren zur herstellung substituierter 3-aryl- butyl-aminverbindungen
DE602004021790D1 (de) Verfahren zur behandlung von parkinson-krankheit
ATE550353T1 (de) Die bindung von mit il-6ralpha komplexiertem il-6 an gp130 verhindernde anti-il-6-antikörper
DE602004032160D1 (de) Verfahren zur Zubereitung von Getränken
EA200802168A1 (ru) Гуманизированное антитело к с-kit
EP1595852A4 (de) Verfahren zur behandlung von ammoniakalischen stickstoffenthaltendem wasser
ATE469908T1 (de) Verfahren zur herstellung von pimecrolimus
ATE529409T1 (de) Verfahren zur herstellung von kristallinen aripiprazolformen
ATE435209T1 (de) Verfahren zur herstellung von montelukast-natrium
DE602005012170D1 (de) Verfahren zur Herstellung von granuliertem L-Lysin enthaltendem Futterzusatz
ATE482966T1 (de) Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
DE602007001103D1 (de) Verfahren zur identifizierung von lrrk2 interagierenden molekülen und zur reinigung von lrrk2
ATE544566T1 (de) Verfahren zur herstellung von dünne metallnanodrähte durch biotemplating
DE60232956D1 (de) Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten
ATE546524T1 (de) Verfahren zur herstellung aktiver scfv-antikörper und bibliotheken dafür
EP2046366A4 (de) Verfahren zur behandlung von altersbedingter makuladegeneration
EP2099446A4 (de) Verfahren zur behandlung von entzündlicher darmerkrankung
EA202191656A1 (ru) Анти-il-36 антитела и способы их применения
EP2001475A4 (de) Verfahren zur behandlung von sarkopenie mit wachstumshormon-sekretagog
ATE516290T1 (de) Verfahren zur herstellung von buprenorphin und derivaten von buprenorphin
EP3790587A4 (de) Verfahren zur behandlung von depression mithilfe von il-23-antikörpern
EP1848834A4 (de) Verfahren zur behandlung von kupferhaltigen materialien
DE602006021324D1 (de) Verfahren zur herstellung stabiler b-lymphozyten
EP4057826C0 (de) Verfahren zur herstellung von proteinmasse

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties